Innate Pharma Announces Its Participation in Upcoming Investor Conference
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
Innate Pharma SA announced that updated efficacy and safety results from the dose-escalation part of the phase 1/2 study with SAR443579/IPH6101 (SAR'579), an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager (NKCE), from a joint research collaboration between Innate Pharma and Sanofi and ANKET platform lead asset, were shared in an oral presentation at the European Hematology Association 2024 Congress in Madrid, Spain on Sunday, June 16 at 11:45 CET.
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
Outcome of Innate Pharma’s 2024 Annual General Meeting
Innate Pharma: Clarification Regarding SAR443579 Designation
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress